Branched and dendritic metallo-carbosiloxanes with OCH2PPh2MLn end-grafted units

A straightforward method for the preparation of metallo carbosiloxanes of type Si(OCH₂CH₂CH₂SiMe₂[OCH₂PPh₂M(CO)_n])₄ (n = 3, M = Ni, 7a; n = 4, M = Fe, 7b; n = 5: M = Mo, 7c; M = W, 7d), Si(OCH₂CH₂CH₂SiMe[OCH₂PPh₂Ni(CO)₃]₂)₄ (8) and Me₂Si(OCH₂CH₂CH₂SiMe[OCH₂PPh₂Ni(CO)₃]₂)₂ (11) is described. The reaction of Si(OCH₂CH₂CH₂SiMeXCl)₄ (1: X = Me, 2: X = Cl) or Me₂Si(OCH₂CH₂CH₂SiMeCl₂)₂ (9) with HOCH₂PPh₂ (3) produces Si(OCH₂CH₂CH₂SiMe₂(OCH₂PPh₂))₄ (4), Si(OCH₂CH₂CH₂SiMe(OCH₂PPh₂)₂)₄ (5) or Me₂Si(OCH₂CH₂CH₂SiMe(OCH₂PPh₂)₂)₂ (10) in presence of DABCO. Treatment of the latter molecules with Ni(CO)₄ (6a), Fe₂(CO)₉ (6b), M(CO)₅(Thf) (6c: M = Mo; 6d: M = W), respectively, gives the title compounds 7a-7d, 8 and 11 in which the PPh₂ groups are datively bound to a 16-valence-electron metal carbonyl fragment.The formation of analytical pure and uniform branched and dendritic metallo carbosiloxanes is based on elemental analysis, and IR, ¹H, ¹³C{¹H}, ²⁹Si{¹H} and ³¹P{¹H} NMR spectroscopic studies. In addition, ESI-TOF mass spectrometric studies were carried out.     

Synthesis and characterization of heavier dioxouranium(VI) dihalides

The synthesis and characterization of the dioxouranium(VI) dibromide and iodide hydrates, UO(2)Br(2)x3H(2)O (1), [UO(2)Br(2)(OH(2))(2)](2) (2), and UO(2)I(2)x2H(2)Ox4Et(2)O (3), are reported. Moreover, adducts of UO(2)I(2) and UO(2)Br(2) with large, bulky OP(NMe(2))(3) and OPPh(3) ligands such as UO(2)I(2)(OP(NMe(2))(3))(2) (4), UO(2)Br(2)(OP(NMe(2))(3))(2) (5), and UO(2)I(2)(OPPh(3))(2)(6) are discussed. The structures of the following compounds were determined using single-crystal X-ray diffraction techniques: (1) monoclinic, P2(1)/c, a = 9.7376(8) A, b = 6.5471(5) A, c = 12.817(1) A, beta = 94.104(1) degrees , V = 815.0(1) A(3), Z = 4; (2) monoclinic, P2(1)/c, a = 6.0568(7) A, b = 10.5117(9) A, c = 10.362(1) A, beta = 99.62(1) degrees , V = 650.5(1) A(3), Z = 2; (4) tetragonal, P4(1)2(1)2, a = 10.6519(3) A, b = 10.6519(3) A, c = 24.0758(6) A, V = 2731.7(1) A(3), Z = 4; (5) tetragonal, P4(1)2(1)2, a = 10.4645(1) A, b = 10.4645(1) A, c = 23.7805(3) A, V = 2604.10(5) A(3), Z = 4, and (6) monoclinic, P2(1)/c, a = 9.6543(1) A, b = 18.8968(3) A, c = 10.9042(2) A, beta =115.2134(5) degrees , V = 1783.01(5) A(3), Z = 2. Whereas 1 and 2 are the first UO(2)Br(2) hydrates and the last missing members of the UO(2)X(2) hydrate (X = Cl --> I) series to be structurally characterized, 4 and 6 contain room-temperature stable U(VI)-I bonds with 4 being the first structurally characterized room temperature stable U(VI)-I compound which can be conveniently prepared on a gram scale in quantitative yield. The synthesis and characterization of 5 using an analogous halogen exchange reaction to that used for the preparation of 4 is also reported.     

Congresses,Conferences, Symposia,Meetings, and Seminars in the Field of Chemical Sciences held in 1995–1996

Information

Congresses, Conferences, Symposia, Meetings, and Seminars in the Field of Chemical Sciences held in 1995–1996     

Using an electrical potential to reversibly switch surfaces between two states for dynamically controlling cell adhesion

Smart surfaces presenting both antifouling molecules with a charged functional group at their distal end, and molecules that are terminated by RGD peptides for cell adhesion, were fabricated and characterized (see picture). By applying potentials of +300 or -300?mV, the surfaces could be dynamically switched to make the peptide accessible or inaccessible to cells.     

4-Silapiperidine and 4-silapiperidinium derivatives: syntheses and structural characterization

A series of novel 4-silapiperidine and 4-silapiperidinium derivatives, with two silicon-bound aryl groups and various N-organyl groups, have been synthesized and structurally characterized (solution ¹H, ¹³C, ¹⁹F, and ²⁹Si NMR spectroscopy; eight crystal structure analyses). These synthetic and structural investigations provide the basis for the development of novel silicon-based drugs containing a 4-silapiperidine or 4-silapiperidinium skeleton.